{
  "trial_id": "NCT00608972",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Women with previously untreated metastatic breast cancer, ER/PR/HER2/neu negative.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Age >= 18",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "ECOG performance status <= 2",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Normal organ and marrow function",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Normal cardiac function as evidenced by LVEF within institutional normal limits",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "History of hypersensitivity reactions to doxil or bevacizumab",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Myocardial infarct or unstable angina within 6 months before enrollment",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Prior anthracycline dose exceeding 360 mg/m2 for doxorubicin (including DOXIL) or 720 mg/m2 for epirubicin.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Proteinuria",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "45-year-old postmenopausal woman with cytologically confirmed breast cancer, HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT00608972",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}